119 related articles for article (PubMed ID: 31847720)
1. Pharmacokinetic properties of Privigen
Morio T; Baheti G; Tortorici MA; Hofmann J; Rojavin MA
Immunol Med; 2019 Dec; 42(4):162-168. PubMed ID: 31847720
[TBL] [Abstract][Full Text] [Related]
2. Pharmacometric Analysis of IgPro10 in Japanese and Non-Japanese Patients With Primary Immunodeficiency.
Luo D; Baheti G; Tortorici MA; Hofmann J; Rojavin MA
Clin Ther; 2020 Jan; 42(1):196-209.e5. PubMed ID: 31910997
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency.
Rojavin MA; Chapdelaine H; Tortorici MA; Praus M; Baheti G; Zhang Y; Hofmann J; Labrosse R; Dicaire R; Haddad E
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):664-670. PubMed ID: 31814328
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of IgPro10 in Japanese primary immunodeficiency patients: a registrational study.
Morio T; Gotoh K; Imagawa T; Morita K; Ohnishi H; Yasui K; Hofmann J; Lawo JP; Shebl A; Rojavin MA
Int J Hematol; 2021 Jun; 113(6):921-929. PubMed ID: 33738703
[TBL] [Abstract][Full Text] [Related]
5. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.
Wasserman RL; Melamed I; Nelson RP; Knutsen AP; Fasano MB; Stein MR; Rojavin MA; Church JA
Clin Pharmacokinet; 2011 Jun; 50(6):405-14. PubMed ID: 21553933
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.
Dorsey MJ; Ho V; Mabudian M; Soler-Palacín P; Domínguez-Pinilla N; Rishi R; Rishi R; Wong D; Rojavin M; Hubsch A; Berger M
J Clin Immunol; 2014 Oct; 34(7):804-12. PubMed ID: 24981039
[TBL] [Abstract][Full Text] [Related]
8. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
[TBL] [Abstract][Full Text] [Related]
9. BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children.
Kriván G; Borte M; Soler-Palacin P; Church JA; Csurke I; Harris JB; Lieberman JA; Melamed IR; Moy JN; Simon R; Aigner S; Lentze S; Staiger C
J Clin Immunol; 2023 Apr; 43(3):557-567. PubMed ID: 36383294
[TBL] [Abstract][Full Text] [Related]
10. Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.
Li Z; McCoy B; Engl W; Yel L
J Clin Immunol; 2021 Aug; 41(6):1331-1338. PubMed ID: 34036490
[TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study.
Anderson JT; Bonagura VR; Cowan J; Hsu C; Mustafa SS; Patel NC; Routes JM; Sriaroon P; Vinh DC; Hofmann JH; Praus M; Rojavin MA
J Clin Immunol; 2021 Feb; 41(2):458-469. PubMed ID: 33409867
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases.
Li Z; Dumas T; Seth Berry N; McCoy B; Yel L
Int Immunopharmacol; 2021 Nov; 100():108044. PubMed ID: 34601202
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study.
Melamed IR; Borte M; Trawnicek L; Kobayashi AL; Kobayashi RH; Knutsen A; Gupta S; Smits W; Pituch-Noworolska A; Strach M; Pulka G; Ochs HD; Moy JN
Eur J Pharm Sci; 2018 Jun; 118():80-86. PubMed ID: 29522908
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies.
Bleasel K; Heddle R; Hissaria P; Stirling R; Stone C; Maher D
Intern Med J; 2012 Mar; 42(3):252-9. PubMed ID: 22212346
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
[TBL] [Abstract][Full Text] [Related]
16. Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study.
Cowan J; Bonagura VR; Lugar PL; Maglione PJ; Patel NC; Vinh DC; Hofmann JH; Praus M; Rojavin MA
J Clin Immunol; 2021 Jan; 41(1):66-75. PubMed ID: 33025378
[TBL] [Abstract][Full Text] [Related]
17. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic evaluation of liposomal amphotericin B (L-AMB) in patients with invasive fungal infection: Population approach in Japanese pediatrics.
Ohata Y; Tomita Y; Suzuki K; Maniwa T; Yano Y; Sunakawa K
Drug Metab Pharmacokinet; 2015 Dec; 30(6):400-9. PubMed ID: 26645511
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
Wasserman RL; Church JA; Peter HH; Sleasman JW; Melamed I; Stein MR; Bichler J;
Eur J Pharm Sci; 2009 Jun; 37(3-4):272-8. PubMed ID: 19491015
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
